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A human immunodeﬁciency syndrome caused
by mutations in CARMIL2
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Human T-cell function is dependent on T-cell antigen receptor (TCR) and co-signalling as
evidenced by immunodeﬁciencies affecting TCR-dependent signalling pathways. Here, we
show four human patients with EBVþ disseminated smooth muscle tumours that carry two
homozygous loss-of-function mutations in the CARMIL2 (RLTPR) gene encoding the capping
protein regulator and myosin 1 linker 2. These patients lack regulatory T cells without
evidence of organ-speciﬁc autoimmunity, and have defective CD28 co-signalling associated
with impaired T-cell activation, differentiation and function, as well as perturbed cytoskeletal
organization associated with T-cell polarity and migration disorders. Human CARMIL2-
deﬁciency is therefore an autosomal recessive primary immunodeﬁciency disorder associated
with defective CD28-mediated TCR co-signalling and impaired cytoskeletal dynamics.
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S
tudying primary immunodeﬁciency disorders (PID) has
provided fundamental insights into principles governing
human tolerance and immunity1. Co-signalling disorders
such as CD40LG, SAP, OX40 or CD27-deﬁciency have
highlighted unique properties of human host defence2. These
disorders impair immune cell interactions and are associated with
selective susceptibility to infectious agents3–5, but also shed light
on the critical role of anti-tumour immune surveillance. In
particular, insufﬁcient T-cell immunity against human gamma
herpesvirus-infected cells can lead to malignancy6. Whereas
SAP-deﬁciency and CD27-deﬁciency predispose speciﬁcally to
Epstein–Barr virus (EBV) infection and EBV-induced lympho-
proliferative disorders, OX40-deﬁciency is associated with
Kaposi’s sarcoma induced by Kaposi’s sarcoma herpesvirus3,7.
T cells are central in adaptive immunity, and T-cell signalling
and co-signalling govern immune defence, immune homoeostasis
and immune surveillance. On antigen encounter, the T-cell
antigen receptor (TCR) becomes engaged and in concert
with context-sensitive co-receptors, such as CD28, ICOS and
OX40, induces T-cell activation, differentiation and function8,9.
Although TCR-dependent signalling is one of the most studied
signalling cascades, knowledge of CD28 co-signalling is
incomplete8,9.
In a murine N-ethyl-N-nitrosourea-mutagenesis screen, the
lymphoid lineage-speciﬁc actin-uncapping protein Rltpr (RGD
motif, leucine-rich repeats, tropomodulin domain and proline-
rich containing; murine homologue to human CARMIL2) was
identiﬁed to be essential for CD28 co-signalling and regulatory
T (Treg) cell development10. Mice expressing mutated Rltpr were
not able to transduce CD28 co-signalling to its effector protein
kinase c theta (Pkcy). Consequently, Rltpr-mutant mice were
speciﬁcally and completely devoid of Treg and thus functionally
phenocopied Cd28 / mice10. Furthermore, truncated Rltpr
expression was associated with increased antibody-dependent
CD28 internalization probably reﬂecting deregulated cytoskeletal
dynamics10.
Human CARMIL2 (RLTPR) was ﬁrst described as a gene
downregulated in cutaneous lesions of patients with psoriasis
vulgaris11. The CARMIL family includes three human paralogs:
CARMIL1 (LRRC16A), CARMIL2 (LRRC16C) and CARMIL3
(LRRC16B). All proteins have a common domain architecture,
that is, one N-terminal pleckstrin homology (PH) domain,
several leucine-rich repeats (LRR), one capping protein binding
region (CBR) domain and one C-terminal proline-rich domain
(PRD)11,12. The CBR domain reduces the afﬁnity of CP for actin
ﬁlament barbed ends and makes them accessible for further actin
polymerisation13. In contrast to CARMIL1 and CARMIL3,
CARMIL2 orchestrates cell polarity by modulating microtubules
and intermediate ﬁlaments12.
In this study, we describe homozygous loss-of-function
CARMIL2 mutations in four human patients from two different
families presenting with the highly unusual phenotype of dissemi-
nated EBVþ smooth muscle tumours (SMT). Our phenotypic
and functional studies demonstrate defective CD28 co-signalling
with impaired T-cell activation, differentiation and function, and
defective cytoskeletal organization associated with T-cell polarity
and migration disorders.
Results
Case reports. Patients P1.1 and P1.2 were born from a con-
sanguineous Yemenite couple. At the age of 2 years, P1.2 pre-
sented with severe failure to thrive, chronic diarrhoea, recurrent
skin and upper airway infections (Table 1). At age 4, P1.2
was diagnosed with an EBVþ latency type III SMT in the liver
(Fig. 1, Supplementary Fig. 1 and Supplementary Table 1).
Tumour staging revealed additional 30 EBVþ SMT in the colon,
terminal ileum and medulla oblongata (Fig. 1 and Table 1). Liver
and brain EBVþ SMT were excised and the patient was treated
by an individualized chemotherapy regimen with oral cyclopho-
sphamide. However, disease progressed with additional lesions
appearing in the brain, liver and spleen. Considering a therapy-
refractory course, the family moved back to Yemen where the
patient deceased.
At the age of 7 years, P1.1 presented with failure to thrive,
recurrent upper airway infections, eczematous dermatitis and
skin warts. Colonoscopy and histopathology revealed several
EBVþ SMT (Table 1 and Supplementary Fig. 1). Further tumour
staging and treatment were hindered by the family’s decision to
return to Yemen. Five years later, P1.1 is reported to have
progressive disease.
Family 1 has six additional children and sibling 2 (S1.2)
reportedly had died at age 19 in Yemen from a similar disease
while the other siblings are healthy (Fig. 2a).
P2.1 and P2.2 were born from a consanguineous Brazilian
couple and have been reported as cases of familial infantile
myoﬁbromatosis (Fig. 2e)14. At the age of 1 year, P2.1 developed
chronic diarrhoea and, from age 4 on, repetitive infections with
Giardia spp., pneumonias and skin warts (Table 1). At age 8,
failure to thrive was documented and consecutively multiple
gastrointestinal, pulmonary and a solid liver EBVþ SMT were
detected (Table 1). P.2.1 received antineoplastic treatment with
methotrexate and vinblastine, but disease progressed and he
deceased at age 14.
P2.2 presented with recurrent chronic eczematous dermatitis
from the age of 1 year on. At age 5 and 6, he had pneumonia and
chickenpox, respectively. At age 6, failure to thrive and multiple
liver and gastrointestinal EBVþ SMT were documented. At age
11, he had a second episode of chickenpox (Table 1). Despite
antineoplastic treatment with methotrexate and vinblastine, the
disseminated soft tissue tumours were progressing and he
deceased at age 12.
In summary, the patients presented with chronic diarrhoea and
failure to thrive, EBVþ SMT, recurrent viral and parasitic infec-
tions and dermatitis (Fig. 1, Supplementary Fig. 1 and Table 1).
Immune phenotype and T-cell EBV-response. As the patients’
clinical course and EBVþ SMT pointed towards defective T-cell
immunity, we performed immune phenotyping (Supplementary
Tables 2 and 3)15. Total peripheral T, B and NK cell counts
mostly were within normal limits (Supplementary Tables 2b
and 3b), but there was a profound reduction of Treg (Fig. 3a).
P2.1 and P2.2 had increased recent thymic emigrants (RTE)
(Supplementary Table 3d) and all patients had a signiﬁcant
increase in naive helper T cells (CD4 TN) and insufﬁcient gain of
central memory helper T cells (CD4 TCM) and central memory
cytotoxic T cells (CD8 TCM) (Fig. 3b and Supplementary
Table 3e). CD27þ IgM IgD switched memory B cells were
at the lower limit or reduced (Supplementary Tables 2c and 3c).
IgG1 and/or IgG4 were reduced in P1.2 or P1.1, respectively,
T-cell dependent-speciﬁc antibodies were reduced in all and
EBV-seroconversion was incomplete in P1.1, P2.1 and P2.2
(Supplementary Tables 2a,d and 3a,g). P1.1 and P1.2 had no
lymphocyte proliferation when stimulated with tetanus and
diphtheria toxoids (Supplementary Table 2e) and P2.1 and
P.2.1 did not show any BCG vaccination scar despite reported
vaccination (Supplementary Table 3g).
To analyse the patients’ T-cell response to EBV, we co-cultured
peripheral blood T cells from P2.1 and P2.2, and two EBVþ
healthy donors (HD) as controls, with autologous irradiated
EBVþ lymphoblastoid cell lines (LCL) over 10 passages. We
found that expansion rates of LCL stimulated T-cell lines (TCL)
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from P2.1 and P2.2 were signiﬁcantly lower than from HD
(Supplementary Fig. 2a). TCL from P2.1 and P2.2 did not secrete
IFN-g on stimulation with autologous LCL but secreted IFN-g on
stimulation with phytohemagglutintin (PHA) (Supplementary
Fig. 2b). IFN-g secretion of P2.2 TCL after stimulation with
human leukocyte antigen (HLA) mismatched LCL suggested that
recognition was not major histocompatibility complex (MHC)-
restricted (Supplementary Fig. 2b). TCL from P2.1 and P2.2 were
unable to secrete IL-4, even after stimulation with PHA
(Supplementary Fig. 2c).
In summary, immune phenotypic and functional studies were
indicative of a T-cell deﬁciency with particular absence of Treg,
insufﬁcient gain of T-cell memory and deﬁcient T-cell response
to EBV.
Genetics. We hypothesized that the T-cell deﬁciency followed an
autosomal recessive Mendelian inheritance pattern with full
penetrance (Fig. 2a,e). For family 1, we performed SNP-based
homozygosity mapping including the father (F1), mother (M1),
Table 1 | Clinical features of CARMIL2-deﬁcient patients.
P1.1 P1.2 P2.1 P2.2
Origin Yemen Yemen Brazil Brazil
Consanguinity Yes Yes Yes Yes
CARMIL2 mutation c.489insG c.489insG c.871þ 1G4T c.871þ 1G4T
CARMIL2 protein
expression
No No No No
Failure to thrive Yes* Yesw Yesz Yesy
EBVþ SMT Gut Gut, liver, spleen, kidney,
brain
Gut, liver, lung Gut, liver
Age at diagnosis of EBVþ
SMT
7 years 4 years 9 years 6 years
Infections Recurrent upper airway
infections
Recurrent upper airway
infections
Recurrent Giardia spp., recurrent
(retention)-pneumonia
Recurrent chickenpox,
pneumonia
Chronic diarrhoea No Yes Yes No
Skin symptoms Eczematous dermatitis,
skin warts
Recurrent abscesses
with S. aureus
Skin warts Eczematous dermatitis
Current state Progressive disease Deceased Deceased Deceased
*Age 7y8m: weight 17.7 kg, Z score  2.2; height 115 cm, Z score  1.8; head circumference 51 cm, Z score 0.5.
wAge 5y2m: weight 7.4 kg, Z score  5.5; height 85 cm, Z score 4.4; head circumference 45 cm, Z score  3.8.
zAge 8y0m: weight 14 kg, Z score  6.2; height 105 cm, Z score 4.4; head circumference not determined.
yAge 12y2m: weight 14.5 kg, Z score  7.23; height 116 cm, Z score 4.59; head circumference 50 cm, Z score  3.26.
a b c
d e f
Figure 1 | Disseminated EBVþ SMT in CARMIL2-deﬁcient patients. (a) Abdominal magnetic resonance (MRI; T1 fat-sat post contrast medium) image of
P1.2 with a tumour ofB6 cm diameter in liver segments I and V–VIII (white arrows). (b) Cranial MRI (T2-WI) of P1.2 with a tumour ofB1.7 cm diameter in
the dorsal medulla oblongata (white arrow). (c) Colonoscopy image of P1.2 with multiple protruding tumors in the colon. (d,e) P2.1 hematoxylin and eosin
(H&E) stains with leiomyogenic tumour cells and (f) EBER in situ hybridization. Scale bars, 50mm. MRI, colonoscopy, tumour histopathology and EBER
stains have been performed for four patients (P1.1, P1.2, P2.1 and P2.2).
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P1.1, P1.2 and S1.1. We found four homozygous regions
each 41Mbp on chromosomes 2 (133707180-139877948), 16
(65905023-83076742) and 17 (837260-2754856; 77793860-
81049726), that segregated with the disease phenotype (Fig. 2b).
Next, we conducted whole-exome sequencing (WES) and com-
bined data sets yielding ﬁve candidate variants inside and
one outside (PLCG1) the homozygous regions (Supplementary
Table 4). PolyPhen and SIFT algorithms predicted two variants to
be damaging (WWOX and DHODH) and two to be tolerated
(ZFHX3 and HSD17B2). The ﬁfth variant was a gain-of-stop indel
mutation in CARMIL2 and was not analysable by PolyPhen and
SIFT algorithms (Supplementary Table 4)16,17. Since mutations in
WWOX and DHODH cause complex malformations clearly
distinct from the patients’ phenotype, we focused on CARMIL2 as
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Figure 2 | Homozygous CARMIL2 mutations segregate with the disease phenotype. (a) Pedigree of family 1 with father (F1), mother (M1), siblings (S1.1
and S1.2) and patients (P1.1 and P1.2). Grey symbols and diagonal bars indicate diseased and deceased subjects, respectively, and CARMIL2 wildtype (Wt)
and CARMIL2 c.489insG mutated (Mut) alleles are depicted for each patient. (b) Schematic representation of chromosome 16, cytogenetic band 16q22.1
and the homozygous region (blue box and bp interval) identiﬁed by SNP chip that harbour CARMIL2 (black vertical line). (c) Electropherograms of family 1
members for CARMIL2 Wt/Mut, Mut/Mut and Wt/Wt alleles. (d) CARMIL2 immunoblots of healthy donor (HD) and family 1 members with vinculin
loading control. (e) Pedigree of family 2 with father (F2), mother (M2) and patients (P2.1 and P2.2). (f) Electropherograms of family 2 members for
CARMIL2 Wt/Mut and Mut/Mut. (g) CARMIL2 immunoblot of HD and family 2 members with vinculin loading control. (h) Schematic representation of
CARMIL2 protein domain architecture and localization of family 1 p.E163fs*4 and family 2 p.D260fs*70 mutations. Immunoblots in (d) and (g) have been
repeated three times.
CD127 FOXP3
a b
P1.1
P2.1
P1.2
P2.2
HD
HD
5.30 4.68
0.060.05
P1.1
CD
25
CD27
HD
TEM TCM
TNTEFF
TEM TCM
TNTEFF
TEM TCM
TNTEFF
TEM TCM
TNTEFF
P1.1
CD
45
R
0
Pe
r c
en
t o
f
CD
8 
T 
ce
lls
0
20
40
60
80
100
TN TCM TEM TEFF
TN TCM TEM TEFF
NS
0.029
NS NS
Pe
r c
en
t o
f
CD
4 
T 
ce
lls
0
20
40
60
80
100
0.002
0.001
0.04 NS
%
 T
R
eg
 
ce
lls
0
2
4
6
HD P
0.001
CD4 T cells CD8 T cells
14.6
0.4 2.9
96.50.2
3.6
13.8 79.9
2.8
62.4
22.80.1
Figure 3 | CARMIL2-deﬁciency impairs CD28-mediated T-cell differentiation. (a) Contour plots of CD25þCD127low and CD25þFOXP3þ Treg and
summary of Treg percentages for six HD (open squares), P1.1 (black circle), P1.2 (black rhomb), P2.1 (black up-pointing triangle) and P2.2 (black down-
pointing triangle). (b) Contour plots of CD4 and CD8 naive (TN, CD45R0
CD27þ ), central memory (TCM, CD45R0þCD27þ ), effector memory
(TEM, CD45R0
þCD27 ) and effector (TEFF, CD45R0CD27 ) T-cells (corresponding percentages are indicated in each square) and summary of
CD4 and CD8 T-cell subtype percentages for six HD and four patients. Small horizontal lines indicate the median. Each symbol represents an individual
donor. Data are representative for four independent experiments with n¼ 2. Signiﬁcance levels are calculated with Welch’s t-test and indicated in the
summary graphs (NS¼ non signiﬁcant).
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the disease causing gene18,19. We conﬁrmed the autosomal
recessive CARMIL2 c.489insG nonsense variant (p.E163fs*4) by
Sanger sequencing and found segregation with the disease
phenotype (Fig. 2a,c,h). CARMIL2 immunoblotting in P1.1 and
P.1.2 LCL showed absent protein expression (Fig. 2d).
For family 2, we analysed the autosomal recessive CARMIL2
c.871þ 1G4T splice-site variant that had been reported as a
WES ﬁnding20. We conﬁrmed CARMIL2 c.871þ 1G4T by
Sanger sequencing and found segregation with the disease
phenotype (Fig. 2e,f). In silico analysis predicted the splice-site
variant to cause skipping of exon 11 resulting in a frame shift and
a premature stop codon (p.D260fs*70) (Fig. 2h). Sanger
sequencing of P2.1 CARMIL2 cDNA detected a splice product
lacking exon 11 and CARMIL2 immunoblotting in P2.1 and P2.2
LCL showed absent protein expression (Supplementary Fig. 3 and
Fig. 2g).
Thus, in both families homozygous loss-of-protein-expression
CARMIL2 mutations segregated with the disease phenotype.
CD28-dependent T-cell function and NK and T-cell cytotoxi-
city. Since murine Rltpr is essential for CD28 co-signalling,
we ﬁrst determined CD28 expression in CARMIL2-deﬁcient
patient CD4 and CD8 T cells and found normal surface levels
(Supplementary Fig. 4a)10. To assess CD28-dependent T-cell
activation, we stimulated CARMIL2-deﬁcient PBMC with anti-
CD3, anti-CD3/CD28 or PMA/ionomycin (P/I) and measured
surface expression of the early activation antigen CD69, the high-
afﬁnity interleukin-2 receptor alpha chain CD25 and the
Treg master transcription factor FOXP3. Patient CD4 and CD8
T cells showed normal TCR-dependent induction of CD69 and
increased CD69 expression after CD28 co-stimulation (Fig. 4a).
In contrast, patient CD4 and CD8 T cells lacked upregulation of
CD25 in response to anti-CD3/CD28 (Fig. 4a). Furthermore
CD25 and FOXP3 co-expression was absent in resting patient
CD4 T cells and could not be induced after anti-CD3 and anti-
CD3/CD28 stimulation (Fig. 4b).
To assess CD28-dependent T-cell proliferation and activation-
induced cell death (AICD), we applied the same stimulation
conditions and analysed CFSE-dilution in combination with
CD25 surface expression and 7-AAD cell viability staining. In HD
and patient CD4 and CD8 T cells, proliferation was modestly
induced after anti-CD3, but only HD T cells showed a robust
proliferative response and concomitant CD25 surface expression
after CD28 co-stimulation (Fig. 5a). After anti-CD3/CD28
stimulation a small fraction of HD CD4 and CD8 T cells
underwent AICD, whereas patient cells did not (Supplementary
Fig. 5). In all experiments, HD and patient T cells responded
equally towards P/I that are bypassing proximal TCR and CD28
co-signalling.
To assess T-cell effector function, we measured cytokine
secretion (IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, IL-17A, GM-CSF,
IFN-g, TNF-a) of stimulated PBMC. On stimulation with anti-
CD3, we observed an increase of cytokine concentrations with the
exception of IL-10 and IL-17A in patients’ PBMC. However,
when stimulated with anti-CD3/CD28, a marked increase in
cytokine concentrations was only seen in HD PBMC. Stimulation
with P/I induced comparable cytokine amounts in HD and
patient cell culture supernatants (Fig. 5b).
NK and T-cell cytotoxicity play crucial roles in tumour
surveillance and control of EBV21,22. We therefore determined
degranulation of and NKG2D expression on NK and CD8 T cells.
NK-cell degranulation in response to co-incubation with the
erythroleukemic cell line K562 was impaired and accompanied by
a decreased expression of NKG2D. In resting CD8 T cells,
NKG2D expression was reduced as well. NK cell and CD8 T-cell
pre-culturing with IL-2 abrogated the observed differences in
degranulation and NKG2D expression (Fig. 6).
In summary, CARMIL2-deﬁcient CD4 and CD8 T cells show
impaired activation, proliferation and effector function in
response to CD28 co-stimulation. Degranulation and NKG2D
expression were impaired in steady state NK and CD8 T cells, but
could be rescued with IL-2.
CD28 co-signalling. The TCR and CD28 co-receptor target an
overlapping but not identical array of signalling intermediates
leading to joint functional outcomes such as T-cell activation,
proliferation and effector function8. The TCR recognizes peptide
antigens presented by MHC molecules, thus conferring antigen
speciﬁcity. CD28 interacts with the invariant co-stimulators
CD80 and CD86, thus leading to full naive T-cell activation23.
The precise positioning of CARMIL2 and its interaction partners
in CD28 co-signalling are currently unknown10. To analyse CD28
co-signalling, we stimulated T lymphoblasts of HD1, HD2, P1.1,
P2.1 and P2.2 with anti-CD3, anti-CD3/CD28 for 2, 5, 10, 15
and 30min and performed immunoblotting and (phospho-) ﬂow
cytometry for essential signalling intermediates (Fig. 7 and
Supplementary Fig. 6). P/I stimulation for 5min served as a
positive control. Phosphorylation of the upstream tyrosine kinase
ZAP70 as well as the serine/threonine kinase PKCy that
participate in the immunological synapse was comparable in
HD and patient cells (Fig. 7)23. Similarly, there was no difference
in phosphorylation of the downstream mitogen-activated protein
kinase ERK1/2 in CARMIL2-deﬁcient and HD T lymphoblasts
(Fig. 7). In contrast, in CARMIL2-deﬁcient T lymphoblasts, the
downstream canonical NF-kB pathway was not activated in
response to CD28 co-signalling as illustrated by aberrant
degradation of IkBa and phosphorylation of NF-kB p65
(Fig. 7). Signalling data obtained by (phospho-) ﬂow cytometry
showed no difference between CD4 and CD8 HD and patient T
cells (Fig. 7 and Supplementary Fig. 6).
We conclude that CARMIL2-deﬁciency selectively impaired
the activation of the canonical NF-kB pathway in a CD28-
dependent manner.
Cytoskeleton dynamics and T-cell migration. The cytoskeleton
plays an important role at almost all stages of the immune
response. Not surprisingly, there is a growing list of PID asso-
ciated with mostly actin-related cytoskeletal defects24. Through
its CBR domain, CARMIL2 is supposed to play an important role
in actin dynamics25. To determine the role of CARMIL2 in
cytoskeleton dynamics and migration, we analysed total amounts
of ﬁlamentous (F)-actin and actin distribution in the leading edge
of HD and patient T lymphoblasts migrating on ICAM1 in 2D.
Quantiﬁcation of total F-actin was comparable between HD and
patient T lymphoblasts in steady state, after PMA-induced
polymerization and latrunculin B-induced depolymerization
(Supplementary Fig. 7a,b). Surface expression of total and active
LFA1—that interacts with ICAM1—and subcellular LFA1 distri-
bution were comparable in HD and patient T lymphoblasts as
well (Supplementary Fig. 7c,d). However, CARMIL2-deﬁcient
T lymphoblasts migrating on ICAM1 in 2D, showed a dispersed
F-actin distribution at the leading edge as compared with a
homogeneous distribution in CARMIL2-proﬁcient cells (Fig. 8a
and Supplementary Fig. 7e). In addition to the effect on F-actin
distribution, localization analysis of a-tubulin showed a markedly
disrupted microtubule network (Fig. 8b, Supplementary Fig. 7f
and Supplementary Movies 1–4). Furthermore, we detected a
global reduction in post-translationally modiﬁed stable acetyl-
and stable detyrosinated glutamyl-a-tubulin monomers in
CARMIL2-deﬁcient T lymphoblasts (Fig. 8c and Supplementary
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Fig. 7g). Microtubule dynamics are crucial for migratory cell
polarity and microtubule depolymerization is associated with
increased spontaneous motility in immune cells26. Accordingly,
patient T lymphoblasts showed dispersed polarity (Fig. 8d) and
increased spontaneous migratory speed both in a 3D collagen gel
and in 2D on ICAM1 (Fig. 8e,f). Pharmacological microtubule
disruption with nocodazole (NDZ) increased migratory speed of
HD cells in 2D but had only mild effects on CARMIL2-deﬁcient
cells suggesting that they already displayed an intrinsic micro-
tubule disruption (Fig. 8g). Although migrating with increased
speed that resulted in higher accumulated migratory distance
(Supplementary Fig. 7h), CARMIL2-deﬁcient T-cell migration
was less orientated with a markedly decreased directness (Fig. 8h)
and reduced Euclidean distance (Supplementary Fig. 7i,j).
Reduced straightness of patient T-cell migration was further
shown by impaired CXCR4-mediated and CXCL12-guided
chemotaxis (Fig. 8i). The reduced chemotactic response could
not be attributed to aberrant expression of cell surface CXCR4
(Supplementary Fig. 7k). Again, NDZ treatment reduced
CXCL12-guided chemotaxis in HD but not patient T
lymphoblasts (Fig. 8j).
In summary, CARMIL2-deﬁcient T cells showed impaired
F-actin distribution at the leading edge and disturbed microtubule
network that were associated with increased LFA1-mediated
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Figure 4 | CARMIL2-deﬁciency impairs CD28-mediated T-cell activation. (a) Representative contour plots of CD25 and CD69 surface expression on
CD4 and CD8 Tcells without (medium) and after stimulation for 48 h with anti-CD3, anti-CD3/CD28 or PMA/ionomycin (P/I). Summary of CD4 and CD8
T-cell CD25 and CD69 surface expression for six HD (open squares), P1.1 (black circle), P1.2 (black rhomb), P2.1 (black up-pointing triangle) and P2.2
(black down-pointing triangle). (b) Contour plots of CD25 surface and FOXP3 expression on CD4 Tcells without (medium) and after stimulation for 48 h
with anti-CD3, anti-CD3/CD28 or PMA/ionomycin (P/I). Summary of CD4 T-cell CD25 surface and FOXP3 expression for four HD and three patients.
Corresponding percentages are indicated in each square. Data are representative for four independent experiments with n¼ 2 (a) or two independent
experiments with n¼ 2 (b). Small horizontal lines indicate the median. Each symbol represents an individual donor. Signiﬁcance levels are calculated with
Welch’s t-test and indicated in the summary graphs (NS¼ non signiﬁcant).
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migratory speed in 2D and LFA1-independent migratory speed in
a 3D collagen network. Accumulated migratory distance was
increased, but Euclidean distance and migration directness as well
as chemokine-guided migration were decreased.
Discussion
We here describe a novel human PID caused by autosomal
recessive mutations in CARMIL2 that abrogated protein expres-
sion. In the context of preserved canonical TCR signalling and
CD28 surface expression, CARMIL2-deﬁcient T cells showed
impaired CD28-mediated co-signalling. Whereas upstream phos-
phorylation of ZAP70 and PKCy and downstream phosphoryla-
tion of ERK1/2 were inducible in CARMIL2-deﬁcient T cells, the
activation of the canonical NF-kB pathway was impaired. Human
CARMIL2-deﬁciency is reminiscent of a murine model of Rltpr-
deﬁciency discovered in a N-ethyl-N-nitrosourea-mutagenesis
screen10. Rltpr-deﬁcient mice also display defective CD28-
mediated co-signalling, associated with defective microclustering
of Pkcy at the immunological synapse10. We could document
regular phosphorylation of PKCy, but were unable to assess
microclustering. It is possible that CARMIL2 contributes to the
stabilization of activated PKCy-microclusters at the immuno-
logical synapse and thereby couples CD28 co-signalling to the
canonical NF-kB pathway10,27. However, precise mechanistic
details on the role of CARMIL2 for CD28-mediated co-signalling
and potentially other signalling pathways need to be addressed in
future studies.
On the cellular level, CARMIL2-deﬁciency did not interfere
with thymic development of conventional CD4 and CD8 T cells.
This is in line with preserved TCR signalling2. In contrast,
CARMIL2-deﬁciency is characterized by impaired naive T-cell
activation, proliferation, effector function and insufﬁcient gain of
T-cell memory, indicative of a globally compromised peripheral
T-cell immunity.
Consistent with an established role of murine CD28
co-signalling for the induction of Foxp3 and the development
of natural Treg, human CARMIL2-deﬁcient T cells, that were able
to express the TCR-inducible activation marker CD69, did not
express CD25 and FOXP3 in response to CD28 co-signalling28.
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Figure 5 | CARMIL2-deﬁciency impairs CD28-mediated T-cell function. (a) Dot and histogram plots of CD25 surface expression and/or CFSE-dilution on
CD4 and CD8 T cells without (medium) and after stimulation for 5 days with anti-CD3, anti-CD3/CD28 or PMA/ionomycin (P/I) and summary of CD4
and CD8 T-cell median CD25 MFI and proliferation percentages for six HD and four patients. (b) Multiplex cytokine assay for IL-2, IL-4, IL-5, IL-10, IL-12, IL-
13, IL-17A, GM-CSF, IFN-g and TNF-a (pgml 1) in the supernatant collected after 48 h from Tcells analysed in a. Small horizontal lines indicate the median.
Each symbol represents an individual donor. Data are representative of four independent experiments with n¼4 and pooled supernatants (b). Signiﬁcance
levels are calculated with Welch’s t-test and indicated in the summary graphs (NS¼ non signiﬁcant).
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Similar to murine Rltpr-deﬁciency, human CARMIL2-deﬁcient
patients were devoid of Treg in the peripheral blood10. At ﬁrst
sight, it may appear surprising, that a lack of Treg in CARMIL2-
deﬁciency was not associated with immune dysregulation.
However, as discussed before and as shown by our data, CD28
co-signalling is necessary to fully activate naive T cells and to
induce proliferation and effector T-cell (Teff) responses23.
Therefore, the complete absence of Treg could be counter-
balanced functionally by impaired Teff responses.
CARMIL2 has been shown to provide a functional link bet-
ween vimentin intermediate ﬁlaments and membrane-associated
actin networks during lamellipodia formation, cell migration and
invadopodia-mediated matrix degradation in ﬁbrosarcoma
cells29. Our studies in CARMIL2-deﬁcient T lymphoblasts
CD3 CD107a
Medium
HD
P2.2
CD
56
NKG2D
NK
CD8
%
 o
f m
ax
.
K562 Medium K562
CD3 CD107a
HD
P2.2
CD
8
%
 o
f m
ax
.
Resting IL-2 cultured
P2.2
HD
Anti-CD3/CD28
Medium
P1.1
P2.1
P2.2
HD
Resting NK
CD
10
7a
 (%
)
0
5
10
15
20
25
30
Med K562
NS
3×10−9
2×10−16
NS
NK/IL−2 cells
CD
10
7a
 (%
)
0
20
40
60
80
100
Med K562
NS
NS
1×10−11
0.0005
Resting NK cells NK/IL-2 cells
CTL
ΔC
D1
07
a 
(M
FI)
×
10
3
0
2
4
6
8
10
HD P
NS
Resting
0
1
2
3
4
5
NK CD8
5×10−6
1×10−10
IL−2 cultured
0
2
4
6
8
NK CD8
NS
0.0024
14.1
1.8 98.8 1.2 97.7 2.3 98.5 1.5 61.1 38.9
97.0 3.0 85.7 14.3 98.6 1.4 56.9 43.1
0.00.00.00.00.00.00.00.0
0.00.00.00.00.00.00.00.0
23.0
19.0
N
KG
2D
 (M
FI)
×
10
3
N
KG
2D
 (M
FI)
×
10
3
a
b
c
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Figure 8 | CARMIL2-deﬁciency leads to defective cytoskeletal organization and migration. Differential interference contrast (DIC) images and
ﬂuorescent pictures of F-actin (a) and tubulin (b) in T lymphoblasts of HD1.1 and P1.1 migrating on ICAM1 (Scale bars, 5 mm). Fluorescent images show the
level of the adhesion plane and details thereof are depicted in the middle. (c) Representative immunoblots showing stable a-tubulin as detected by acetyl-
or detyrosinated glutamyl-a-tubulin in HD1.1 and P1.1. p38 and global a-tubulin serve as loading controls (nZ3). (d) Time-lapse video microscopy images of
HD1.2 and P1.2 T lymphoblasts migrating on ICAM1. Time in seconds is depicted for each frame (Scale bars, 10mm). (e) Spontaneous migration of T
lymphoblasts (nZ110) in a 3D collagen matrix. For HD1.1, HD1.2, P1.1, P1.2 three and for HD2.1, HD2.2, P2.1, P2.2 two independent experiments are shown.
(f) Spontaneous migration of T lymphoblasts on ICAM1 in 2D (nZ123 in three independent experiments). (g) x-fold migratory speed of control (co) versus
nocodazol (NDZ) pretreated T lymphoblasts is depicted (nZ128 in two independent experiments). (e–g) Red horizontal lines indicate the median.
(h) Directness of migration on ICAM1 was quantiﬁed from T lymphoblast tracks (mean±s.e.m., n¼99). (i,j) Chemotactic T-cell migration through
5 mm pores towards CXCL12 was analysed. When indicated T lymphoblasts were pretreated with nocodazole (NDZ). Three (i) or two (j) independent
experiments with two technical replicates were done (mean±s.e.m.). Signiﬁcance levels are calculated for patient T lymphoblasts in relation to HD
within corresponding assays using the two-sided unpaired Student’s t-test and are indicated in the summary graphs (NS¼ non signiﬁcant).
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showed impaired actin distribution in the leading edge and a
severely disturbed microtubule network associated with increased
spontaneous migratory speed but decreased directness and
chemokine-directed migration. It is possible that high migratory
speed of CARMIL2-deﬁcient T cells results in suboptimal
scanning of peptide:MHC-complexes on professional antigen-
presenting cells and thus affects antigen-speciﬁc T-cell
activation30. In line with that, we found impaired proliferation
and cytokine production in co-cultures of antigen-presenting
autologous EBVþ LCL and CARMIL2-deﬁcient TCL. However,
keeping in mind the impaired canonical NF-kB pathway
discussed before, it is difﬁcult to weight the particular contri-
butions of disturbed antigen-scanning and CD28 co-signalling
on T-cell activation. Despite increased migratory speed of
CARMIL2-deﬁcient T cells, impaired directness and
chemokine-mediated migration might additionally impair Teff
responses in CARMIL2-deﬁcient patients. Defective microtubule
stability has been associated with increased spontaneous
migration in 3D networks and decreased chemokine-guided
migration of T cells31,32. Thus, CARMIL2 now emerges as a
critical regulator of cytoskeletal dynamics in T cells. At this point,
we cannot demarcate speciﬁc effects of defective T-cell activation
and defective T-cell migration accounting for the state of
immunodeﬁciency.
The most prominent clinical ﬁnding in all four CARMIL2-
deﬁcient patients was EBVþ SMT. EBVþ SMT is a very rare
tumour entity usually associated with secondary immunodeﬁ-
ciency disorder, for example, in the context of HIV-infection or
iatrogenic immunosuppression in organ transplant patients15.
In human OX40-deﬁciency, HHV8þ Kaposi’s sarcoma cells
strongly expressed OX40L and impaired OX40 signalling on
immune cells was supposed to be a key pathogenic factor3.
However, we did not detect increased expression of CD80 or
CD86 on EBVþ SMT.
In human SAP, CD27 and CD70 co-signalling deﬁciencies,
orthotopic EBV-infection causes hemophagocytic lymphohistio-
cytosis (HLH) and/or highly proliferating and immunogenic
B-cell lymphomas, respectively4. In striking contrast, CARMIL2-
deﬁciency is not associated with EBV-induced B-cell proli-
feration, but rather with a slowly proliferating and pauci-immune
SMT associated with dystopic EBV-infection33. Since CD28 co-
signalling is essential to activate naive T cells and to induce Teff
responses, EBVþ SMT in the context of CARMIL2-deﬁciency
might evade anti-tumour immunity and indicate a particular
importance of CD28 co-signalling in controlling this tumour
entity23. On the other side, even in the absence of EBVþ
lymphoproliferative disorder, we found that CARMIL2-deﬁcient
T cells also had decreased capacity to recognize EBVþ
autologous LCL. Further studies may unravel why EBV causes
leiomyomatosis rather than B-cell proliferation in CARMIL2-
deﬁcient patients.
Of note, exposure to recombinant IL-2 partially restored
markers of NK and cytotoxic T-cell function that are crucial to
prevent EBV-triggered lymphoproliferative disorders34. This
observation might not only be relevant for potential immuno-
modulatory effects in vivo, it further might indicate that besides
CD28 co-signalling additional receptor systems could depend on
CARMIL2. From a technical point of view, IL-2 responsiveness
also severely hampered our attempts to reconstitute the T-cell
phenotype in vitro by lentiviral gene transfer.
In summary, CARMIL2-deﬁciency is a novel primary auto-
somal recessive human immunodeﬁciency disorder highlighting a
role for CARMIL2 as orchestrator of CD28 co-signalling and
cytoskeletal dynamics necessary for Treg development, adequate
T-cell activation, proliferation, differentiation, effector function as
well as T-cell polarity and migration.
Methods
Patients. Patients were referred to the Dr von Hauner Children’s Hospital, Lud-
wig-Maximilians-Universita¨t, Munich, Germany and the Department of Pediatric
Gastroenterology, Federal University of Minas Gerais, Belo Horizonte, Brazil.
Informed consent was obtained according to current ethical and legal guidelines.
The study protocol was approved by the Institutional Review Board at the
University Hospital, Ludwig-Maximilians-Universita¨t, Munich, Germany
(Project Number 381-11). The study was conducted in accordance with the
Declaration of Helsinki.
LCL-responsive T-cell lines. For initiating T-cell lines (passage 1), 1 106 per-
ipheral blood mononuclear cells (PBMC) from patients P2.1 and P2.2 and from
two EBV-seropositive healthy donors (HD1 and HD2) were co-cultured with
gamma-irradiated (80Gy) autologous EBVþ lymphoblastoid cell lines (LCL) at
a 10:1 ratio (PBMC:LCL) in a total volume of 2ml T-cell medium consisting of
AIM-V lymphocyte medium supplemented with 10% pooled human serum, 2mM
L-glutamine, 10mM HEPES and 1% amphotericin B. To prevent expansion of FCS-
reactive T cells, stimulator LCL were continuously cultured in RPMI 1640 medium
supplemented with 10% human serum, 2mM L-glutamine, 1% nonessential amino
acids, 1mM sodium pyruvate, 2mM L-glutamine and 50mgml 1 gentamicin as
described35. After 48 h, 50Uml 1 IL-2 (Novartis) was added to the culture
medium. The T-cell lines were restimulated every two weeks in the same way
and split when needed. After ten passages, the lines contained predominately
(495%) CD3þCD8þ cells and few (o5%) CD3þCD4þ cells. Speciﬁcity of
T cells was tested by incubating 5 104 target cells (autologous or allogeneic
HLA-mismatched LCL) with 5 104 T cells in a ﬁnal volume of 200ml T-cell
medium. After 24 h of co-culture, ELISA (R&D Systems) for measuring
supernatant cytokines was performed.
Genetic analysis. Genomic DNA of family 1 subjects F1, M1, P1.1, P1.2 and S1.1
(Fig. 2a) was genotyped using the Genome-wide Human SNP array 6.0 on a GEO
Platform GPL6801 (Affymetrix) and used to prepare exome libraries using the
SureSelect XT Human All Exon V4þUTRs kit (Agilent Technologies). Barcoded
libraries were sequenced on a SOLiD 5500 XL next-generation sequencing platform
(Life Technologies) at the Dr von Hauner Children’s Hospital sequencing facility to
an average coverage depth of 80 reads. Bioinformatic data processing followed an in
house pipeline: Reads were aligned to the human reference genome (version hg19)
using LifeScope Analysis Suite 2.5.1 (Life Technologies, Carlsbad, CA, USA) using
standard parameters. The lane data for each sample were merged and the PCR
duplicates were removed using SAMtools version 1.18 (ref. 36). SAMtools was also
used to call SNPs with the command: ‘mpileup –M 300 –I –g –D -C50 –S’. Small
insertions and deletions (indels) were identiﬁed using DinDel version 1.01 (ref. 37),
by ﬁrst identifying putative indels for each sample Individually, and then re-running
the DinDel on the pooled set of samples from family A with the previously identiﬁed
indels as suggested variants. Variants were annotated and their manifestation at the
mRNA and protein level identiﬁed according to the Ensembl Database (version 68).
In addition, information on variant frequencies was collected from HapMap (HM)38,
1000 genomes (TG)39, NHLBI Grand Opportunity Exome Sequencing Project (NH)
and ExAC40.The WES approach for genomic DNA of family 2 subjects F2, M2, P2.1
and P2.2 has been published before20. The c.489insG and c.871þ 1G4T CARMIL2
mutations were conﬁrmed by Sanger sequencing (see Supplemantary Table 5 for
primer information). CARMIL2 cDNA was reverse transcribed from P2.1T
lymphoblast total mRNA (RevertAid H Minus Reverse trascriptase; ThermoFisher
Scientiﬁc) and skipping of exon 11 was conﬁrmed by Sanger sequencing
(see Supplemantary Table 5 for primer information).
Cell culture and stimulation. PBMC were isolated from healthy donors and
patients by Ficoll-Hypaque (Pharmacia) density gradient centrifugation. PBMC were
maintained in RPMI 1640 supplemented with 2mM glutamine, 100Uml 1 peni-
cillin, 100mgml 1 streptomycin and 10% FCS (ThermoFisher) in a 5% CO2 incu-
bator at 37 C. Cell lines have been tested negative for mycoplasma by PCR using
VenorGeM Mycoplasma Detection Kit (MP0025, Sigma-Aldrich). Stimulation
titration curves were established (Supplementary Fig. 4b). For T-cell activation,
proliferation and cytokine secretion experiments PBMC were stimulated with anti-
CD3-coupled beads (Bio-anti-CD3, OKT3 from eBioscience coupled with anti-Biotin
MACSiBeads from Miltenyi Biotec) at a ratio of 10:1 with and without 1mgml 1
soluble anti-CD28 (CD28.2, eBioscience) or with 0.5 ngml 1 phorbol 12-myristate
13-acetate (PMA) and 1mM ionomycin (Sigma-Aldrich). For T-cell signalling ana-
lysis by immunoblotting and (phospho-) ﬂow cytometry, T lymphoblasts were
induced from PBMC with 5 ngml 1 PMA, 1mM ionomycin and 100Uml 1 IL-2
(Novartis) for two days and cultured for 8–16 additional days in complete RPMI
1640 substituted with 100Uml 1 IL-2. For T-cell migration assays and analysis of
cytoskeletal proteins, PBMCs were activated for four days with 1mgml 1 phyto-
hemagglutinin (Remel, Dartford). Cells were then maintained in medium containing
20ngml 1 recombinant IL-2 (Proleukin, Novartis). Activated human T lympho-
blasts were used at day 10–14 following stimulation.
Flow cytometry. Treg cells were stained with APC-H7-anti-CD3 (SK7, 1:50), APC-
anti-CD4 (SK3, 1:100), PE-anti-CD25 (M-A251, 1:50) (all BD Biosciences) and
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FITC-anti-CD127 (eBioRDR5, 1:50, eBioscience). Intracellular staining with
PerCP-Cy5.5-anti-FOXP3 (PCH101, 1:25) was performed using FOXP3 staining
kit (eBioscience). Memory T cells were surface stained with APC-H7-anti-CD3
(SK7, 1:50), PerCP-anti-CD4 (SK3, 1:10), PacB-anti-CD8 (RPA-T8, 1:100), APC-
anti-CD28 (CD28.2, 1:200), PE-Cy7-anti-CD45R0 (HI100, 1:100), PE-anti-CCR7
(3D12, 1:5) (all BD) and FITC-anti-CD27 (O323, 1:50, eBioscience). Proliferative
response and AICD were measured by labelling PBMC with 2.5 mM carboxy-
ﬂuorescein diacetate succinimidyl ester (CFSE, ThermoFisher), 7-aminoactino-
mycin D (7-AAD, 2.5 mgml 1, BD), APC-H7-anti-CD3 (SK7, 1:50), PE-anti-
CD25 (M-A251, 1:50), APC-anti-CD8 (SK1, 1:200) (all BD) and PC5-anti-CD4
(13B8.2, 1:100, Beckman Coulter) 5 days after stimulation. Degranulation of NK
cells and CTLs (cytotoxic T lymphocytes) was determined by surface staining with
PerCP-anti-CD3 (SK7, 1:100), FITC-anti-CD8 (SK1, 1:100), APC-anti-CD56
(NCAM16.2, 1:100), PE-anti-CD107a (H4A3, 1:50) and PE-Cy7-anti-NKG2D
(1D11, 1:20) (all BD). Expression analysis of total and high-afﬁnity LFA1 was
performed with conformation-speciﬁc anti-LFA1 monoclonal antibodies clone 38
(AbD Serotec) and clone 24 (kind gift from N. Hogg) and mouse IgG1 (MOPC-21)
from Biozol (Eching) as isotype control at 37 C, 7% CO2, followed by goat anti-
mouse IgG-APC (BioLegend) on ice, all used at concentration of 10 ml ml 1.
CXCR4 was detected with PE-anti-CXCR4 (clone 44717, 10 ml per 106 cells, R&D
Systems). For (phospho-) ﬂow analysis, 2.5 106 T lymphoblasts were stimulated
with titrated antibody concentrations (Supplementary Fig. 6a) by cross-linking of
1 mgml 1 anti-CD3 (UCHT1) and/or 10 mgml 1 anti-CD28 (CD28.2) with
10mgml 1 goat anti-mouse IgG all from BD for the indicated time. Cells were
ﬁxed and permeabilized with ﬁxation and permeabilization kit from Molecular
Probes in 90% methanol. Before staining of surface antigens, unbound goat anti-
mouse IgG was blocked with normal mouse IgG (Invitrogen). The permeabilized
cells were stained with the following titrated intracellular antibodies detecting:
ERK1/2 phosphorylated at T202 and Y204 (#4377, 197G2, 1:200), ZAP70 phos-
phorylated at Y319 (#2717, 65E4, 1:400), PKCy phosphorylated at T538 (#9377,
1:200), rabbit AlexaFluor488-conjugated secondary antibody (#4412, 1:1000) all
purchased from Cell Signalling and AlexaFluorA647-anti-NFkB p65 phosphorylated
at S529 (K10-895.12.50, 1:10) and AlexaFluorA647-anti-IkBa (25/IkBa/MAD-3,
1:10) both purchased from BD. Stained cells were analysed using a BD LSRII Fortessa
or BD CANTOII ﬂow cytometer. Gating strategies are shown in Supplementary
Fig. 11. Data analysis was performed with FlowJo software (TreeStar).
Cytokine analysis. Culture supernatants were collected 48 h after stimulation,
pooled from four technical replicates and assayed for IL-2, IL-4, IL-5, IL-10, IL-12,
IL-13, IL-17A, TNF-a, GM-CSF and IFN-g using a 10-plex cytokine assay kit
(L500000CA5) on a Bio-Plex 200 System (BioRad) following the manufacturer’s
instructions.
NK and CD8 T-cell degranulation and NKG2D expression. Degranulation of
resting and activated NK cells was measured by surface staining of CD107a without
(medium-cultured cells) and 3 h after stimulation with K562 cells at a ratio of 1:1
(ref. 41). The erythroleukemic cell line K562 (ATCC, CCL-243) was used as
target cell line. NK cells were cultured in medium containing 600Uml 1 IL-2
(Novartis) for 48 h to assess degranulation of activated NK cells. CTL (cytotoxic T
lymphoblasts) degranulation was evaluated in T lymphoblasts 48 h after
stimulation with 1.25 mgml 1 phytohemagglutinin-L (PHA-L, Sigma) and
200Uml 1 IL-2 (Novartis). CTL degranulation was calculated by the difference in
median ﬂuorescence intensity of CD107a of CTLs stimulated with CD3/CD28
coated microbeads (ThermoFisher Scientiﬁc) at a ratio of 1:10 for 3 h and medium-
cultured cells.
Immunoblotting and CD28 co-signalling. For CARMIL2 expression, CD28
co-signalling and cytoskeletal analyses cells were left unstimulated or stimulated as
mentioned above, respectively. Protein isolation, SDS-PAGE and immunoblotting
were performed as published elsewhere42. The following primary and secondary
antibodies were used: CARMIL2 (HPA041402, 1:400, Sigma-Aldrich and
ab122717, 1:400, Abcam), actin (sc-8432, 1:500, Santa Cruz), detyrosinated
a-tubulin (Glu-tubulin, AB3201, 1:500, Millipore), acetylated a-tubulin (6-11-B-1,
ab24610, 1:1,000, Abcam), a-tubulin (DM1A, CP06,1:2,000, Calbiochem), vinculin
(V9131, 1:10,000, Sigma-Aldrich), p38 (#9212; 1:1,000, Cell Signalling) and goat-
anti-mouse-HRP (1:4,000) and goat-anti-rabbit-HRP (1:5,000) both purchased
from Jackson ImmunoResearch. For (phospho)-protein analysis, the generation
and stimulation of T lymphoblasts was carried out as described above and the
following antibodies were used: ERK1/2 phosphorylated at T202 and Y204 (#4377,
197G2, 1:1,000), ZAP70 phosphorylated at Y319 (#2717, 65E4, 1:1,000), PKCy
phosphorylated at T538 (#9377, 1:1,000), NF-kB phosphorylated at S536 (#3033,
1:1,000) and rabbit HRP-conjugated secondary antibody (#7074, 1:3,000) all
purchased from Cell Signalling. Uncropped immunoblots are shown in
Supplementary Figs 8–10.
Quantiﬁcation of F-actin. To quantify the amount of F-actin, T lymphoblasts
were left untreated or were incubated with 100 nM phorbol-myristate-acetate
(PMA, Sigma-Aldrich) for 5min or with 0.5 mM latrunculin B (Calbiochem) for
10min at 37 C followed by ﬁxation with 4% paraformaldehyde. Fixed cells were
permeabilized with 0.01% Triton X-100 (Sigma-Aldrich), stained with phalloidin-
Alexa594 (1:500, Invitrogen) and F-actin amount was quantiﬁed by ﬂow cytometry
analysis using a BD FACSCalibur and FlowJo software (Tree Star).
Migration assays. Two-dimensional migration of T lymphoblasts on ICAM1
were analysed on m-slides (Ibidi) coated with 0.15 mg recombinant human ICAM1/
Fc (R&D Systems) per channel over night at 4 C. Slides were blocked with 1%
BSA/PBS for 1 h before use. A total of 5 104 T lymphoblasts per channel were
allowed to migrate in a steam-saturated incubation chamber at 37 C, 7% CO2, and
images were taken every 8 s for 1 h with a Plan-Apochromat 40 /1.3 NA oil
objective using an Axiovert 200 microscope (all Zeiss Microscopy). The migratory
speed, accumulated and Euclidean distance and directness were quantiﬁed using
ImageJ software (National Institute of Health) and the chemotaxis and migration
tool V2.0 from Ibidi. Cells migratingo80mm in 30min were not included as they
were mostly stationary. To analyse the three-dimensional migration of T lym-
phoblasts, a collagen matrix was prepared using 1mgml 1 collagen type I from rat
tail according to the manufacturer’s instructions (Ibidi). Activated T lymphoblasts
were embedded into the collagen matrix at a concentration of 1 105 cells within a
m-slide. Analysis and quantiﬁcation of cell migration was performed as described
above by taking pictures every 8 s for 30min using an EC Plan-Neoﬂuar 20 /0.50
NA. Migration assays in response to CXCL12 were performed using 6.5mm
transwells with 5 mm pore size (Corning). 5 105 T lymphoblasts were added on
the top of each ﬁlter. Medium containing 2.5% serum and 25mM Hepes was
placed at the bottom and supplemented with 100 ngml 1 CXCL12 (R&D Systems)
when indicated. Assays were run for 2 h at 37 C and 7% CO2. Migrated lym-
phocytes were collected and quantiﬁed using CountBright Absolute Counting
Beads (Molecular Probes) and a BD FACSCalibur.
Immunoﬂuorescence imaging. Immunoﬂuorescence staining of migrated cells
was performed on 15mm glass coverslips, coated with 0.7 mg recombinant human
ICAM1/Fc (R&D Systems). Migration of 1 105 T lymphoblasts was allowed for
1 h at 37 C, 7% CO2 in HBSS/25mM HEPES. Adherent cells were ﬁxed with 3%
paraformaldehyde, permeabilized with 0.1% Triton X-100 and coverslips were
incubated with an anti-LFA1 antibody (clone 38, 10 mgml 1, AbD Serotec)
followed by goat-anti-mouse-Alexa 488 (Molecular Probes; 1:150) or Phalloidin-
Alexa 546 (1:100, Invitrogen). For localization of tubulin, polarized T cells were
ﬁxed in half-concentrated PHEM buffer (30mM PIPES, 12.5mM HEPES, 5mM
EGTA, 1mM MgCl2; pH 6.9) freshly supplemented with 0.25% glutaraldehyde and
0.25% Triton X-100 for 5min. Unreacted glutaraldehyde was quenched for 10min
with 1mgml 1 of freshly dissolved sodium borohydride and T cells were sub-
jected to anti-tubulin antibody (YL12, ab6160, 1:200 Abcam), followed by goat-
anti-rat-Cy3 (1:200, Jackson ImmunoResearch). ProLong Gold Antifade Reagent
(Life Technologies) was used as mounting medium. Fixed samples were imaged at
room temperature with an ApoTome-attached Observer Z1, and a Plan-Apoc-
hromat 100 /1.4 NA oil objective (Zeiss Microscopy). Bright-ﬁeld images were
performed using differential interference contrast (DIC). An AxioCam MRm
camera and the AxioVision Software (Zeiss Microscopy) were used for image
acquisition and image analysis.
Immunohistochemistry and in situ hybridization. For immunohistochemistry,
the following antibodies and dilutions were used on a Ventana Benchmark XT
autostainer with ultraView Universal DAB detection kits (Ventana Medical Sys-
tems): muscle speciﬁc actin (DAKO; HHF35; 1:200), calponin (DAKO; CALP;
1:300), pan-cytokeratin (Beckman Coulter; KL-10; 1:150), desmin (DAKO; D33;
1:300), CD34 (Cell Marque; QBEnd/10; 1:800), CD117 (DAKO; A4502; 1:400),
S100 (DAKO; Z0311; 1:3,000), Ki67 (DAKO; MIB-1; 1:150), CD80 (Abcam;
EPR1157(2); 1:300), p53 (Leica Microsystems; DO-7; 1:25), C-MYC (Abcam; Y69;
1:100), LMP1 (Diagnostic BioSystems; CS1/CS2/CS3/CS4; 1:100), LMP2A (Acris
antibodies; 15F9; 1:100), EBNA2 (Merck Millipore; R3; 1:25) and the viral tran-
scription factor ZEBRA (Santa Cruz Biotechnology; BZ1; 1:100). CD86 (BIOZOL
Diagnostica; 1B3; 1:100) was stained manually. Chromogenic in situ hybridization
for EBV-encoded RNA (EBER) was performed using ﬂuorescein-labeled oligonu-
cleotide probes (INFORM EBER Probe, Ventana). Fluorescence in situ hybridi-
zation for C-MYC (Zyto Vision) was performed as described before43.
Statistical analysis. Data were analysed with the software environment R (version
3.2.3) or Prism 5 (GraphPad) for statistical computing and graphics. Normal
Gaussian distribution of data sets was tested using Shapiro-Wilk normality test.
Signiﬁcances between two groups were calculated with the two-sided unequal
variances Welch’s t-test or two-sided unpaired Student’s t-test. Two-way ANOVA
was used for comparisons of more than two groups. P values of o0.05 were
considered signiﬁcant.
Data availability. CARMIL2 variant data that support the ﬁndings of this study
have been deposited in ClinVar with the primary accession codes SCV000322745
and SCV000322755. Other data that support the ﬁndings of this study are available
from the corresponding author upon request.
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